Actinogen Medical announced early clinical study data for Xanamem, a drug designed to lower brain cortisol and intended for the treatment of Alzheimer’s disease, at the Alzheimer’s Association International Conference (AAIC) 2016, held in Toronto, Canada. Xanamem works by blocking excess cortisol production in the hippocampus and frontal cortex, two brain…
News
Researchers at the Technical University of Madrid, in Spain, have discovered that changes in nerve signaling patterns exist in the brains of people with mild cognitive impairment, a condition believed to precede Alzheimer’s disease and other dementias. From the study ”A multicenter study of the early detection of synaptic…
In mid-July, scientists at the Washington University Medical School, Saint Louis, published a study that inspired awe in fellow researchers — an updated map of the cerebral cortex of the human brain, identifying nearly 100 new areas. The exceedingly intricate and updated map, published in the journal Nature…
Data from a Phase 2b clinical trial showing that vTv Therapeutics‘s investigational drug, azeliragon, slows cognitive decline in patients with mild Alzheimer’s disease were presented at the Alzheimer’s Association International Conference 2016 in Toronto this week. Azeliragon is a drug that blocks the receptor RAGE (Receptor for Advanced Glycation Endproducts) in…
On July 26, a different kind of happening interrupted the usual bustle of activity at this year’s Alzheimer’s Association International Conference (AAIC 2016) in Canada. Attending scientists became the first viewers (at a sneak-peek preview before the North American premiere) of a new kind of full-length documentary film — one that reveals untold…
Researchers at the University of Sussex in England have built a protein closely resembling amyloid-β, except for the fact that it is not capable of aggregating. The new protein, described in a report titled, “A critical role for the self-assembly of Amyloid-β1-42 in neurodegeneration,“ published in the…
Each year on World Brain Day, July 22 the year, the World Federation of Neurology (WFN) dedicates a brain awareness campaign to a different topic. Tomorrow’s will draw our attention to the aging brain — and the diseases that damage it. The campaign hopes to be a wake-up call for politicians and…
North Carolina-based Muses Labs will show its latest technology and services July 24-28 at the Alzheimer’s Association International Conference (AAIC) 2016 in Toronto, Canada. Expected to spur most interest is a presentation by the company’s chief technology officer, John Q. Walker — results from a pilot study of the MEND Protocol, a…
That running can boost our memory to the same degree or more than brain training is an old observation that still puzzles scientists worldwide. But a new study by National Institute on Aging scientists is providing information about how that happens and emphasizing that to keep memory from fading, people should keep running. The study, “…
California-based researchers from the Buck Institute for Research on Aging created a method capable of screening substances that might be effective in age-related conditions such as Alzheimer’s disease — with the help of roundworms. The new tool, presented at the Allied Genetics Conference in Orlando, Florida, on July 15,…
Recent Posts
- Trial testing cholesterol-lowering med as potential Alzheimer’s intervention October 5, 2026
- At-home injection version of Alzheimer’s drug now available in US September 8, 2026
- FDA designation may speed new treatment for Alzheimer’s psychosis August 3, 2026
- Study reports Alzheimer’s treatment gains in long-term care July 6, 2026
- Awareness month event has new name: Do What You Love to End Alzheimer’s June 1, 2026